J.B. Ugland Venture AS

Venture Capital

Portfolio

companies

MicrofluidX

MicrofluidX provides next-generation bioreactors for cell research and manufacturing.

Richard Coulling

Series A8 December 2022

£3.3M

MicrofluidX secures £3.3m Series A from Longwall Ventures and other backers to advance cell culture platforms.

The Stevenage enterprise raised the capital from Longwall Ventures and a syndicate of backers to fund trials and product development.

"Advanced therapy manufacturing is hindered by out of date, inadequate manufacturing technologies,"

— Antoine Espinet, CEO